Surgical Innovations Share Discussion Threads

[z1co] 02/2/2024 12:30

The trading update was definitely better than expectations as is the outlook for 2024 but the price has not risen further due to too many shares in the hands of MM's hence you can still buy at below mid at 0.675p.

Once the overhang is cleared the share price will start to rise higher.

[z1co] 30/1/2024 07:06

29 January 2024 - NEW SHARE TIP

The trading update issued today by the specialist supplier to the minimally invasive surgery market could signal a change in fortunes for the company. The company supplies innovative, high quality medical products primarily for use in minimally invasive surgery and these include surgical instruments, port access systems and retraction devices. These are sold directly in the UK and are also exported through a global network of distribution partners. The group's UK subsidiary also distributes specialist products for third party manufacturers and these are used in laparoscopy, bariatric and metabolic surgery as . . .

[sharetips] 29/1/2024 18:45

Agreed Z1co. The shares look way oversold and have been tipped in cityconfidential today. Www.cityconfidential.co.uk

[z1co] 29/1/2024 16:47

A first BLUE finish in nearly 6 months and a lot more blue's to come.

Volume was over 4 million of which most were buys.

[z1co] 29/1/2024 14:29

Hold them until at least the results , shares will rise.The fall was over done on uncertainty.The company has traded marginally ahead of expectations in H2.

Sales in H2 were 13% higher than the first 6 months.

Outlook for 2024 is also upbeat.

David Marsh, CEO of Surgical Innovations Group Plc, said: "Despite a challenging 2023, the Company finished the year with record sales and entered 2024 with an encouraging order book".

The share price at 0.6p was even lower than 2020 during the covid-19 period.

Was way over sold.

[justiceforthemany] 29/1/2024 13:26

Holding here but come on its hardly awe inspiring! Struggling to break even...

[grupo guitarlumber] 29/1/2024 12:02

Surgical Innovations shares soar on higher annual revenue predictions
January 29, 2024 at 10:26 am


(Alliance News) - Surgical Innovations Group PLC on Monday said it expects to report a surge in its annual revenue figures.

Shares in Surgical Innovations jumped 14% to 0.69 pence each in London on Monday morning.

The Leeds, England-based surgical and medical instrument manufacturer expects revenue in 2023 to be approximately GBP12.0 million, an increase of 6.2% compared with GBP11.3 million in 2022.

Surgical Innovations added that group revenue continued to grow in the second half of the year, in line with the board's expectations.

Meanwhile, sales for the second half of the year were about 13% higher than the first half.

Chief Executive David Marsh says: "Despite a challenging 2023, the company finished the year with record sales and entered 2024 with an encouraging order book. The recent actions taken to improve operational efficiencies, together with continued increasing sales momentum, give the board confidence that we have put the business onto a sustainable growth trajectory for 2024 and beyond."

By Sabrina Penty, Alliance News reporter

Comments and questions to [e-mail]

[grupo guitarlumber] 29/1/2024 12:00

Current trading and outlook

While continued industrial action in the NHS has impacted the volume of elective surgeries and slowed some of the progress with evaluations, it is not anticipated to affect Q1 sales. Across the Company's distribution network, expected sales remain on track to deliver management forecasts. Some of the supply chain issues seen last year have impacted OEM sales, but these are now resolved and are not expected to have a material bearing on Q1 performance.

[z1co] 29/1/2024 12:00

Alliance News

Surgical Innovations Group PLC, up 15% at 0.69 pence, 12-month range 0.50p-2.35p. The surgical and medical instrument manufacturer says revenue in 2023 is expected to be approximately GBP12.0 million, an increase of 6.2% compared with GBP11.3 million in 2022. It says that group revenue continued to grow in the second half of the year, in line with the board's expectations. Sales for the second half of the year were about 13% higher than the first half. Chief Executive David Marsh says: "Despite a challenging 2023, the company finished the year with record sales and entered 2024 with an encouraging order book. The recent actions taken to improve operational efficiencies, together with continued increasing sales momentum, give the board confidence that we have put the business onto a sustainable growth trajectory for 2024 and beyond."

[grupo guitarlumber] 29/1/2024 11:59

Strengths

The company shows low valuation levels, with an enterprise value at 0.51 times its sales.

The company's share price in relation to its net book value makes it look relatively cheap.

Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.

The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.

Historically, the company has been releasing figures that are above expectations.

Weaknesses

As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.

[z1co] 29/1/2024 11:42

MM's have increased the bid to 0.60p but can still buy at 0.685p.

The fear factor that drove the shares down from 2.0p to 0.6p has been completely eliminated after today's trading update.

Shares will keep rising back towards the 2p mark.

[z1co] 29/1/2024 09:44

100% upside before their results and it will still be very cheap.

[z1co] 29/1/2024 08:19

The price has dropped from 2p to 0.6p over the 6 months on fears of poor trading but today's TU is very upbeat.

The outlook for 2024 is also very bullish.

I expect the shares to recover very strongly in 2024.

[z1co] 29/1/2024 08:15

Year-end 2023 Trading Update



Record sales and operational efficiency programme on track



Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, provides an update on trading for the year ended 31 December 2023, with sales marginally head of market expectations.



Unaudited Financials

Revenues for the year are expected to be approximately £12.0m, an increase of 6% compared with the prior year (2022: £11.3m). Group revenues continued to grow in H2 in line with the Board's expectations, with key markets and OEM sales in particular performing strongly. Sales for the second half of the year were approximately 13% higher than the first half. The Group expects to report a positive adjusted EBITDA1 of £0.2m, in-line with expectations. Operational improvements continue to be implemented in the new financial year and are expected to enhance future profitability.



The closing net cash2 balances of the Group stood at approximately £0.36m at 31 December 2023 (30 June 2023: £0.38m), with available gross cash resources at 31 December 2023 of £2.21m (30 June 2023: £2.41m) including an undrawn invoice discounting facility of £1.0m (30 June 2023: £1.0m).



UK sales remained strong in H2 2023, driven by the resonance of the sustainability messaging for both the NHS and Private Healthcare providers. Growing global acceptance of the need to adopt more sustainable solutions in healthcare is also driving growth in key markets in Europe, APAC and ROW. Despite supply chain challenges in H2 2023, the OEM business produced strong sales and carried a positive order book into 2024.



The recently implemented operating efficiency programme, which includes the re-introduction of a 5-day working week, is on track to deliver further improvements to the gross margin in 2024.



Current trading and outlook

While continued industrial action in the NHS has impacted the volume of elective surgeries and slowed some of the progress with evaluations, it is not anticipated to affect Q1 sales. Across the Company's distribution network, expected sales remain on track to deliver management forecasts. Some of the supply chain issues seen last year have impacted OEM sales, but these are now resolved and are not expected to have a material bearing on Q1 performance.



David Marsh, CEO of Surgical Innovations Group Plc, said: "Despite a challenging 2023, the Company finished the year with record sales and entered 2024 with an encouraging order book. The recent actions taken to improve operational efficiencies, together with continued increasing sales momentum, give the Board confidence that we have put the business onto a sustainable growth trajectory for 2024 and beyond."

[z1co] 29/1/2024 08:14

!FOLLOWFEED
Year-end 2023 Trading Update:

Record sales and operational efficiency programme on track

Surgical Innovations Group Plc (AIM: SUN), the designer, manufacturer and distributor of innovative technology for minimally invasive surgery, provides an update on trading for the year ended 31 December 2023, with sales marginally head of market expectations.

[mjneish] 13/1/2024 19:26

This company seems to have been around for a pretty long time, and doesn't seem to have gone anywhere.

Annual sales:

1999: £1.3m
2000: £1.79m
2001: £1.847m
2002: £2.224m
2003: £2.75m
2004: £3.03m
2005: £4.02m
2006: £4.46m
2007: £4.77m
2008: £4.312m
2009: £4.541m
2010: £7.045m
2011: £7.602m
2012: £7.639m
2013: £8.553m
2014: £4.029m
2015: £5.468m
2016: £6.089m
2017: £8.752m
2018: £10.969m
2019: £10.733m
2020: £6.329m
2021: £9.126m
2022: £11.340m

[justiceforthemany] 04/1/2024 19:07

Why has seemingly everyone sold out then?

[luckyabbeygale] 29/12/2023 01:01

No. This is a strong buy at these levels.

[justiceforthemany] 28/12/2023 23:14

Bad news has leaked?
Insider selling?

[justiceforthemany] 01/12/2023 11:43

buywell has disappeared. Typical.
This company has a good balance sheet and with surgical volumes rising and good products seems overdone.
ADDED.

[barrenwuffet2] 25/10/2023 19:30

This share has been at or under 1pence for a few weeks now with no good news or explanation. I’m thinking this is because there's no good news to come. I don’t think you can get out at the moment even if you wanted to.

[mandate] 26/9/2023 07:11

I tend to agree with gnnmartin - the current share price is a good opportunity - the roadmap appears sensible - dyor

[john148] 26/9/2023 00:13

I sold the majority of my holding about 10 years ago when the share price was nearly 12p. I still hold a few shares but wouldn't jump in even at these lows. That's not because I'm fearful but because I've lost confidence in the company delivering anything substantive in the future.